Migraine Clinical Trial
Official title:
Randomisierte Kontrollierte Studie Zur Wirkung Von Yoga Bei Chronischen Kopfschmerzen im Jugendalter
Verified date | July 2017 |
Source | Universität Duisburg-Essen |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A randomized controlled trial to investigate the efficacy of yoga on tension type headache and / or migraine in adolescents between 12 and 16 years, consisting of a four group design which includes an 12 week yoga course and a three-month follow-up period. Both adolescent and one parent will be randomized either to yoga or no treatment. Primary outcome will be pain frequency in adolescents considering pain catastrophizing of parents.
Status | Completed |
Enrollment | 45 |
Est. completion date | July 2017 |
Est. primary completion date | March 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 12 Years to 16 Years |
Eligibility |
Inclusion Criteria: Adolescent: - tension type headache and/or migraine minimum at 4 days per month - willingness to participate at least 10 out of 12 yoga sessions - physical and cognitive ability to participate in light physical, breathing and relaxation exercises - good german language Parents: - willingness to participate at least 10 out of 12 yoga sessions - physical and cognitive ability to participate in light physical, breathing and relaxation exercises - good german language Exclusion Criteria: - pregnancy or lactation - attending a yoga class within the last 3 months prior to the study |
Country | Name | City | State |
---|---|---|---|
Germany | Elisabeth Krankenhaus | Essen | |
Germany | Kinderkrankenhaus St. Marien | Landshut |
Lead Sponsor | Collaborator |
---|---|
Universität Duisburg-Essen |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Pain frequency adolescent | Measurement of pain frequency after yoga intervention via headache diary | Week 12 | |
Secondary | Pain frequency adolescent | Measurement of pain frequency after follow-up period via headache diary | Week 24 | |
Secondary | Pain duration adolescent | Measurement of pain duration after yoga intervention via headache diary | Week 12 | |
Secondary | Pain duration adolescent | Measurement of pain duration after follow-up period via headache diary | Week 24 | |
Secondary | Pain intensity adolescent | Measurement of pain intensity after yoga intervention via headache diary | Week 12 | |
Secondary | Pain intensity adolescent | Measurement of pain intensity after follow-up period via headache diary | Week 24 | |
Secondary | Quality of life adolescent self-assessment | Measurement of quality of life in self-assessment after yoga intervention via the kidscreen 27 questionnaire | Week 12 | |
Secondary | Quality of life adolescent self-assessment | Measurement of quality of life in self-assessment after follow-up period via the kidscreen 27 questionnaire | Week 24 | |
Secondary | Quality of life adolescent external assessment | Measurement of quality of life in external assessment by one parent after yoga intervention via the kidscreen 27 questionnaire | Week 12 | |
Secondary | Quality of life adolescent external assessment | Measurement of quality of life in external assessment by one parent after follow-up period via the kidscreen 27 questionnaire | Week 24 | |
Secondary | Pain disability adolescent self-assessment | Measurement of pain disability in self-assessment after yoga intervention via the paediatric pain disability index (P-PDI) | Week 12 | |
Secondary | Pain disability adolescent self-assessment | Measurement of pain disability in self-assessment after follow-up period via the paediatric pain disability index (P-PDI) | Week 24 | |
Secondary | Pain disability adolescent external assessment | Measurement of pain disability in external assessment by one parent after yoga intervention via the paediatric pain disability index (P-PDI) | Week 12 | |
Secondary | Pain disability adolescent external assessment | Measurement of pain disability in external assessment by one parent after follow-up period via the paediatric pain disability index (P-PDI) | Week 24 | |
Secondary | Pain coping adolescent | Measurement of pain coping in self-assessment after yoga intervention via the Paediatric Pain Coping Inventory Revise (PPCI-R) | Week 12 | |
Secondary | Pain coping adolescent | Measurement of pain coping in self-assessment after follow-up period via the Paediatric Pain Coping Inventory Revise (PPCI-R) | Week 24 | |
Secondary | Depression adolescent | Measurement of Depression in self-assessment after yoga intervention via the Depressions Inventar für Kinder und Jugendliche (DIKJ) | Week 12 | |
Secondary | Depression adolescent | Measurement of Depression in self-assessment after follow-up period via the Depressions Inventar für Kinder und Jugendliche (DIKJ) | Week 24 | |
Secondary | Stress adolescent | Measurement of Stress in self-assessment after yoga intervention via the Problem Questionnaire (PQ) | Week 12 | |
Secondary | Stress adolescent | Measurement of Stress in self-assessment after follow-up period via the Problem Questionnaire (PQ) | Week 24 | |
Secondary | Pain catastrophizing parents | Measurement of parents pain catastrophizing in self-assessment by one parent after follow-up period via the Pain Catastrophizing Scale for Parents (PCS-P) | Week 12 | |
Secondary | Pain catastrophizing parents | Measurement of parents pain catastrophizing in self-assessment by one parent after follow-up period via the Pain Catastrophizing Scale for Parents (PCS-P) | Week 24 | |
Secondary | Quality of life parents | Measurement of parents quality of life in self-assessment by one parent after yoga intervention via the WHO Quality of Life Bref questionnaire (WHOQol-Bref) | Week 12 | |
Secondary | Quality of life parents | Measurement of parents quality of life in self-assessment by one parent after follow-up period via the WHO Quality of Life Bref questionnaire (WHOQol-Bref) | Week 24 | |
Secondary | Depression parents | Measurement of parents depression in self-assessment by one parent after yoga intervention via the Beck-Depression-Inventar (BDI) | Week 12 | |
Secondary | Depression parents | Measurement of parents depression in self-assessment by one parent after follow-up period via the Beck-Depression-Inventar (BDI) | Week 24 | |
Secondary | Stress parents | Measurement of parents stress in self-assessment by one parent after yoga intervention via the Cohen's Perceived Stress Scale (PSS-10) | Week 12 | |
Secondary | Stress parents | Measurement of parents stress in self-assessment by one parent after follow-up period via the Cohen's Perceived Stress Scale (PSS-10) | Week 24 | |
Secondary | Adverse events adolescent | Adverse events within the yoga course period of adolescents | Week 12 | |
Secondary | Adverse events parents | Adverse events within the yoga course period of parents | Week 12 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT06192173 -
Patent Foramen Ovale Closure in Migraine
|
||
Completed |
NCT05525611 -
Cabergoline as a Preventive Treatment for Chronic Migraine
|
N/A | |
Recruiting |
NCT03832998 -
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
|
Phase 3 | |
Enrolling by invitation |
NCT04196933 -
Analysis of Vestibular Compensation Following Clinical Intervention for Vestibular Schwannoma
|
N/A | |
Not yet recruiting |
NCT06428838 -
Eptinezumab as an Adjunct to Standard of Care for Migraine in an Acute Emergency Context
|
Phase 3 | |
Completed |
NCT06304675 -
Manageable Environmental Factors in Migraine
|
||
Completed |
NCT04084314 -
Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study
|
Phase 4 | |
Recruiting |
NCT05517200 -
Pilot Study for a Machine Learning Test for Migraine
|
||
Completed |
NCT04179474 -
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
|
Phase 1 | |
Recruiting |
NCT04603976 -
Registry for Migraine - Clinical Core
|
Phase 4 | |
Completed |
NCT03597529 -
CHOCOlate MeLatonin for AdolescenT MigrainE
|
Phase 2 | |
Completed |
NCT04197349 -
Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman
|
Phase 1 | |
Recruiting |
NCT05891808 -
miR-155 Expression in Episodic and Chronic Migraine
|
||
Active, not recruiting |
NCT05064371 -
Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan
|
Phase 3 | |
Suspended |
NCT04069572 -
Vibratory Stimulation for the Treatment of Chronic Pain
|
N/A | |
Not yet recruiting |
NCT04859374 -
Chronic Pain and Conditioned Pain Modulation After on Line-behavioral Approach
|
N/A | |
Not yet recruiting |
NCT03083860 -
Evaluation of Migraine Management Mobile App Combined With Electrophysiological Measurements for Identification of Migraine Attack Risk and Beneficial Preventive Actions.
|
N/A | |
Completed |
NCT02905227 -
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
|
Phase 1 | |
Enrolling by invitation |
NCT02532023 -
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients
|
Phase 4 | |
Completed |
NCT02108678 -
One-Day Intervention for Depression and Impairment in Migraine Patients
|
N/A |